Ginkgo Bioworks (DNA)
(Delayed Data from NYSE)
$0.27 USD
-0.02 (-5.46%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $0.27 0.00 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DNA 0.27 -0.02(-5.46%)
Will DNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNA
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
DNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
Why the Market Dipped But Ginkgo Bioworks Holdings, Inc. (DNA) Gained Today
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Other News for DNA
Ginkgo Bioworks: From Growth To Value
Ginkgo Bioworks: Underperform Rating Due to Financial Strain and Uncertain Strategic Outcomes
Ginkgo Bioworks Reports Second Quarter 2024 Financial Results
DNA Stock Earnings: Ginkgo Bioworks Holdings Misses EPS, Beats Revenue for Q2 2024
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2024 Earnings Call Transcript